The first drugs developed entirely through artificial intelligence could be available to patients by the end of this decade, predicts Alex Zhavoronkov, CEO of AI drug discovery startup Insilico Medicine.
A Five-Year Horizon for AI Drug Breakthroughs
“I would be surprised if we don’t see it over the next five to six years,” said Zhavoronkov. “I hope we will be the first ones – we have more than 40 programmes internally – but you never know,” he added. Zhavoronkov’s optimism reflects a broader shift in the pharmaceutical industry, where AI is increasingly seen as a game-changer. While no AI-designed drug has yet received regulatory approval, progress is accelerating.
Industry Eyes Cost and Time Cuts with AI
The pharmaceutical sector has long highlighted AI’s potential to dramatically reduce the time and cost of drug development. Companies are now moving from experimentation to late-stage trials. Japanese firm Takeda Pharmaceutical, for example, is in the final phase of clinical testing for a psoriasis treatment selected using AI, with trial results expected later this year.
Insilico’s End-to-End AI Integration Sets It Apart
What differentiates Insilico, according to Zhavoronkov, is its full-spectrum use of AI. Unlike many firms that apply AI only at select stages, Insilico integrates the technology across the entire drug development lifecycle — from target identification to drug optimization — to deliver candidates ready for human trials.
Global Footprint and Billion-Dollar Valuation
Insilico operates across the U.S., China, the Middle East, and Canada. The company recently refiled for a public listing on the Hong Kong stock exchange following a successful private funding round that pushed its valuation past US$1 billion.
Outlook: A Turning Point for Drug Discovery
As the AI race in biotech heats up, Insilico Medicine is leading a major shift in drug discovery. According to freemalaysiatoday.com, AI-designed therapies could soon reach pharmacy shelves, transforming R&D and patient care.
